Buzz Stocks: Under Armour Inc, SAExploration Holdings, Inc., and Dipexium Pharmaceuticals Inc

Today's stocks to watch in the news include Under Armour Inc (NYSE:UA), SAExploration Holdings, Inc. (NASDAQ:SAEX), and Dipexium Pharmaceuticals Inc (NASDAQ:DPRX)

by Celeste Taylor

Published on Oct 25, 2016 at 9:58 AM
Updated on Oct 25, 2016 at 10:04 AM

U.S. stocks are cautiously higher as traders react to a slew of blue-chip earnings. Among equities in focus today are athletic apparel retailer Under Armour Inc (NYSE:UA), oil-and-gas stock SAExploration Holdings, Inc. (NASDAQ:SAEX), and biotech Dipexium Pharmaceuticals Inc (NASDAQ:DPRX). Here's a quick look at what's driving UA, SAEX, and DPRX.

  • UA is trading down 13.9% at $32.64 --  and earlier hit a two-year low of $32.25 -- after issuing lackluster full-year revenue growth guidance, which overshadowed an earnings beat. Within the first 30 minutes of trading, Under Armour Inc (NYSE:UA) has seen about 18.2 million shares traded -- nearly eclipsing its current annual high of 19.5 million shares traded in a single day. The athletic apparel maker was hit with a downgrade to "market perform" from "outperform" at William Blair, and additional downgrades could be in store, with 18 of 28 analysts rating the shares a "strong buy," and only one "sell" or worse rating on the record. 

  • SAEX is up 53.9% at $11.51, after announcing it received $24.4 million in tax credits from Alaska's Department of Revenue, and could receive up to $60.5 million in additional tax credits over the next year. To say SAExploration Holdings, Inc. (NASDAQ:SAEX) has struggled lately would be putting it lightly; the stock is down over 95% since the beginning of 2016. While SAEX's short interest is up 248.3% over the last two reporting periods, only a mere 6.3% of SAEX's float is currently sold short, which would take not even a day to cover, at the stock's average daily rate, hinting at little sideline cash available to fuel an extended rally.
  • DPRX is plummeting this morning, down 83.9% at $2.05, after its Locilex cream, intended to treat diabetic foot ulcers, failed to meet its goal in a late-stage trial. DPRX is now down 83% in 2016, and earlier touched a new all-time low of $1.90. There are likely plenty of bears celebrating today's sharp plunge, with Dipexium Pharmaceuticals Inc's (NASDAQ:DPRX) short interest up 35.1% over the last two reporting periods.

Stay on top of overnight news & big morning movers. Sign up now for Schaeffer's Opening View.


A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.
Wall Street Roars Higher Amid Civil Unrest
Investors weighed a mixed bag of jobs data
AstraZeneca Stock Flat Despite COVID-19 Vaccine News
AstraZeneca saw a rise in capacity for its COVID-19 vaccine candidate
The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.